{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:27:21Z","timestamp":1794565641964,"version":"4.9.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>The separation of benign from malignant mesothelial proliferations is often a difficult pathologic problem. <jats:italic toggle=\"yes\">UHRF1<\/jats:italic> (ubiquitin-like with plant homeodomain and ring finger domains-1) is a regulator of DNA methylation and an epigenetic driver of various human cancers. It has recently been reported that <jats:italic toggle=\"yes\">UHRF1<\/jats:italic> is overexpressed in mesotheliomas. We asked whether UHRF1 immunohistochemistry could be used to separate benign from malignant mesothelial proliferations. Initial studies showed that UHRF1 stained mesothelial cells but also endothelial and other non-neoplastic cells, so that accurate counting of positive mesothelial cells was difficult. Therefore, we ran dual UHRF1-AE1\/AE3 stains on 2 tissue microarrays containing 40 reactive mesothelial proliferations and 61 mesotheliomas and only counted UHRF1 staining in keratin-positive cells. On average 10.3\u00b18.6% (mean\u00b1SD; range: 0% to 36, median: 6.8%) of epithelioid mesothelioma cells stained compared with 5.3\u00b14.8% (range: 0% to 15%, median: 4.1%) of reactive epithelial mesothelial cells. This difference was statistically significant but there was too much overlap to use diagnostically. In contrast, 37\u00b126% (range: 2.5% to 95%, median: 31%) of cells in sarcomatoid mesotheliomas compared with 1.2\u00b11.2% (range: 0% to 3.0%, median: 1.0%) of cells in reactive spindle cell mesothelial proliferations stained. To confirm this difference we stained whole sections of 21 sarcomatoid mesotheliomas and 19 cases of organizing pleuritis. Staining of mesothelial cells was seen in 2.1\u00b12.4% (range: 0% to 6.8%, median: 1.0%) of organizing pleuritis cases and 44\u00b122% (range: 14% to 90%, median: 41%) of sarcomatoid mesotheliomas. We conclude that dual UHRF1-AE1\/AE3 immunohistochemistry is very useful for separating benign spindle cell mesothelial proliferations from sarcomatoid mesotheliomas.<\/jats:p>","DOI":"10.1097\/pas.0000000000001840","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T03:04:46Z","timestamp":1636772686000},"page":"840-845","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["UHRF1 Immunohistochemical Staining Separates Benign Reactive Spindle Cell Mesothelial Proliferations From Sarcomatoid Mesotheliomas"],"prefix":"10.1097","volume":"46","author":[{"given":"Hang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pathology, Vancouver General Hospital"},{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vancouver General Hospital"},{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vancouver General Hospital"},{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/PAS.0000000000001565","article-title":"The separation of benign and malignant mesothelial proliferations: new markers and how to use them","volume":"44","author":"Churg","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317692205","article-title":"UHRF1: the key regulator of epigenetics and molecular target for cancer therapeutics","volume":"39","author":"Sidhu","year":"2017","journal-title":"Tumor Biol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"51946","DOI":"10.18632\/oncotarget.17393","article-title":"The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer","volume":"8","author":"Ashraf","year":"2017","journal-title":"Oncotarget"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"10201","DOI":"10.1038\/ncomms10201","article-title":"A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat Commun"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"BSR20181065","DOI":"10.1042\/BSR20181065","article-title":"UHRF1 mediates cell migration and invasion of gastric cancer","volume":"38","author":"Zhang","year":"2018","journal-title":"Biosci Rep"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1245\/s10434-011-2194-1","article-title":"UHRF1 promotes cell growth and metastasis through repression of p16 ink4a in colorectal cancer","volume":"19","author":"Wang","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jtho.2020.08.024","article-title":"UHRF1 is a novel druggable epigenetic target in malignant pleural mesothelioma","volume":"16","author":"Reardon","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","article-title":"Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center","volume":"15","author":"Galateau Salle","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-021-03077-7","article-title":"CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations","author":"Salisbury","year":"2021","journal-title":"Virchows Arch"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/CDKN2A loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2017.07.015","article-title":"The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center","volume":"67","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bjc.6605717","article-title":"UHRF1 is a novel diagnostic marker of lung cancer","volume":"103","author":"Unoki","year":"2010","journal-title":"Br J Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:05:49Z","timestamp":1749416749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001840","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}